LifeMD Wegovy Pill Telehealth ProgramvsHenry Meds Compounded Oral Semaglutide (Dissolvable Tablets / Drops)

The therapeutic agent is oral semaglutide (Wegovy pill), a GLP-1 receptor agonist that curbs appetite, slows gastric emptying, and improves blood-sugar handling. LifeMD's role is the service layer: a licensed clinician evaluates eligibility, prescribes the branded drug, and provides ongoing monitoring, dose adjustments, and fulfillment.

The active ingredient is semaglutide, the same GLP-1 receptor agonist found in branded products, prepared by a compounding pharmacy as a dissolvable tablet or sublingual drop. The intent is absorption through the tissues of the mouth to bypass the digestive breakdown that limits swallowed peptide pills, though real-world absorption from these routes is reported to be low and variable.

Because LifeMD dispenses the same FDA-approved oral semaglutide 25 mg, the expected efficacy mirrors the OASIS 4 trial (NEJM, 2025): roughly 13.6% mean weight loss at 64 weeks (up to ~16.6% with full adherence). The added telehealth coaching and check-ins are designed to support adherence, which is the main driver of real-world results.

Semaglutide as a drug class has strong efficacy data, but there are no large-scale outcomes trials for compounded sublingual or oral-troche formulations specifically, and reported bioavailability of sublingual routes is only about 3-10%. Expected weight loss is therefore less predictable than with FDA-approved oral semaglutide; results depend heavily on the formulation, dose actually absorbed, and adherence.

Side effects come from the medication itself, primarily GI effects like nausea, diarrhea, vomiting, and constipation, usually most pronounced during dose escalation. Serious but rare risks include pancreatitis; the drug carries a boxed warning for thyroid C-cell tumors. LifeMD clinicians monitor and adjust dosing to manage tolerability.

Expect the usual GLP-1 GI effects: nausea, diarrhea, vomiting, and constipation, often worst early on. An added concern with compounded products is potential variability in potency and purity, since these are not FDA-reviewed. Rare serious risks like pancreatitis exist across the class. Discuss your full history with a licensed provider and report problems promptly.

As of May 2026, the Wegovy pill runs about $149/month for starter and 4 mg doses (4 mg rising to $199 after April 15, 2026) and around $299/month for higher maintenance doses; Novo's 12-month subscription can save up to $600/year on the pill. A separate LifeMD membership or visit fee applies on top of medication cost. Verify current pricing with LifeMD.

As of May 2026, reported all-inclusive pricing for Henry's oral/sublingual semaglutide ranges roughly $149-$249/month (covering medication, provider visits, supplies, and shipping), with higher doses adding about $100/month. It is cash-pay only with no insurance accepted. Pricing varies by source and changes over time, so confirm directly with Henry Meds.

Adults with obesity or overweight with a weight-related condition who qualify after a telehealth evaluation in any of the 50 states. The same contraindications as Wegovy apply, including a personal or family history of medullary thyroid carcinoma or MEN2. A clinician makes the final prescribing decision.

Adults seeking weight management who qualify after a telehealth evaluation and who are comfortable with a compounded (non-FDA-approved) medication. Standard GLP-1 contraindications apply, including personal or family history of medullary thyroid carcinoma or MEN2 and a history of pancreatitis. A prescription is still required.